{"changeSha256":"3ed99d134731263263ee886a70a239574bb34cf6d4a5418fd2ee2caba27f2553","changedAt":"2026-11-14","changedFields":[{"after":"FDA-approved as Gvoke, Baqsimi and other glucagon products","before":"U.S. label record","field":"Status"},{"after":"A peptide hormone that raises blood sugar, FDA-approved since 1960. The cited label covers Gvoke for severe low blood sugar and Gvoke VialDx as a diagnostic aid.","before":"A peptide hormone. The cited U.S. label distinguishes Gvoke for severe hypoglycemia from Gvoke VialDx for diagnostic use.","field":"Profile summary"},{"after":"Smaller controlled crossover studies described in the label found that nearly all participants reached the target rise in blood sugar within 30 minutes. The label keeps the severe-hypoglycemia and diagnostic uses separate.","before":"The cited label describes subcutaneous Gvoke for severe hypoglycemia in people with diabetes aged two years and older, and intravenous Gvoke VialDx as a diagnostic aid in adults. The product, route and indication must remain distinct.","field":"Evidence note"},{"after":"Gvoke VialDx, Gvoke, Baqsimi","before":"Gvoke VialDx","field":"Related names"},{"after":"dailymed-glucagon-359982a8-ec5c-4927-8c0f-89771e0f942b-v2, fda-drugs-nda012122-1960-11-14-3232418447c3, fda-drugs-nda201849-2015-05-08-7be1ec311130, fda-drugs-nda210134-2019-07-24-69c8d7c9e55f, fda-drugs-nda212097-2019-09-10-289a38c344bd","before":"dailymed-glucagon-359982a8-ec5c-4927-8c0f-89771e0f942b-v2","field":"Cited source records"},{"after":"U.S. National Library of Medicine [sources: dailymed-glucagon-359982a8-ec5c-4927-8c0f-89771e0f942b-v2]; U.S. Food and Drug Administration [sources: fda-drugs-nda212097-2019-09-10-289a38c344bd]","before":"U.S. National Library of Medicine [sources: dailymed-glucagon-359982a8-ec5c-4927-8c0f-89771e0f942b-v2]","field":"Named organizations"},{"after":"name: dailymed-glucagon-359982a8-ec5c-4927-8c0f-89771e0f942b-v2; aliases: dailymed-glucagon-359982a8-ec5c-4927-8c0f-89771e0f942b-v2, fda-drugs-nda212097-2019-09-10-289a38c344bd, fda-drugs-nda210134-2019-07-24-69c8d7c9e55f; category: dailymed-glucagon-359982a8-ec5c-4927-8c0f-89771e0f942b-v2; status: dailymed-glucagon-359982a8-ec5c-4927-8c0f-89771e0f942b-v2, fda-drugs-nda012122-1960-11-14-3232418447c3, fda-drugs-nda210134-2019-07-24-69c8d7c9e55f, fda-drugs-nda212097-2019-09-10-289a38c344bd; summary: dailymed-glucagon-359982a8-ec5c-4927-8c0f-89771e0f942b-v2, fda-drugs-nda012122-1960-11-14-3232418447c3; evidenceNote: dailymed-glucagon-359982a8-ec5c-4927-8c0f-89771e0f942b-v2","before":"name: dailymed-glucagon-359982a8-ec5c-4927-8c0f-89771e0f942b-v2; aliases: dailymed-glucagon-359982a8-ec5c-4927-8c0f-89771e0f942b-v2; category: dailymed-glucagon-359982a8-ec5c-4927-8c0f-89771e0f942b-v2; status: dailymed-glucagon-359982a8-ec5c-4927-8c0f-89771e0f942b-v2; summary: dailymed-glucagon-359982a8-ec5c-4927-8c0f-89771e0f942b-v2; evidenceNote: dailymed-glucagon-359982a8-ec5c-4927-8c0f-89771e0f942b-v2","field":"Claim citations"}],"currentVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/glucagon/versions/4/","version":4},"id":"profile:glucagon:v4","interpretationBoundary":"This event describes a PeptideScanner public-version change. It does not by itself establish that the cited source changed, that a scientific conclusion changed, or that source monitoring is continuous.","kind":"profile-status-changed","notice":"We added a plain-language reader guide with cited answers, re-checked the Gvoke and Gvoke VialDx label, and added Drugs@FDA approval records for glucagon products.","peptideSlugs":["glucagon"],"previousChangeEvent":{"path":"/corrections/v1/profiles/glucagon/v3.json","sha256":"69f39b506b0c4a22a6c480c975bdd77063fbc0a8495432ae2ad1fe9f20f1396b"},"previousVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/glucagon/versions/3/","version":3},"schemaVersion":"peptidescanner-public-correction-lineage-event/v1","sourceRecords":[{"id":"dailymed-glucagon-359982a8-ec5c-4927-8c0f-89771e0f942b-v2","name":"DailyMed · U.S. National Library of Medicine","sourceClass":"A","title":"GVOKE VIALDX (glucagon) injection, solution · SPL version 2 · published 2026-07-09","url":"https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=359982a8-ec5c-4927-8c0f-89771e0f942b&version=2","verifiedAt":"2026-07-22"},{"id":"fda-drugs-nda012122-1960-11-14-3232418447c3","name":"Drugs@FDA via openFDA","sourceClass":"A","title":"Drugs@FDA application NDA012122 · original submission status AP · 1960-11-14 · dataset 2026-08-13","url":"https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA012122%22&limit=1","verifiedAt":"2026-08-14"},{"id":"fda-drugs-nda212097-2019-09-10-289a38c344bd","name":"Drugs@FDA via openFDA","sourceClass":"A","title":"Drugs@FDA application NDA212097 · original submission status AP · 2019-09-10 · dataset 2026-08-13","url":"https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA212097%22&limit=1","verifiedAt":"2026-08-14"}],"subject":{"slug":"glucagon","type":"profile"}}
